Ikena Oncology, Inc. (IKNA)
| Previous close | 1.6800 |
| Open | 1.6700 |
| Bid | 1.6500 x 100 |
| Ask | 1.7000 x 200 |
| Day's range | 1.6500 - 1.7000 |
| 52-week range | 1.0200 - 7.0000 |
| Volume | |
| Avg. volume | 304,979 |
| Market cap | 80.832M |
| Beta (5Y monthly) | 0.49 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.5700 |
| Earnings date | 08 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.00 |
Simply Wall St.It's Unlikely That Ikena Oncology, Inc.'s (NASDAQ:IKNA) CEO Will See A Huge Pay Rise This Year
Key Insights Ikena Oncology's Annual General Meeting to take place on 7th of June CEO Mark Manfredi's total...
GlobeNewswireUPDATE – Ikena Oncology Announces Strategic Update
Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Exploring strategic options to maximize shareholder value BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”) today announced discontinuation of the clinical IK-930 program, the Company’s TEAD1- selective Hippo pathway inhibitor and continued clinical development
- GlobeNewswire
Ikena Oncology Announces Strategic Update
Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Exploring strategic options to maximize shareholder value BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”) today announced discontinuation of the clinical IK-930 program, the Company’s TEAD1- selective Hippo pathway inhibitor and continued clinical development
